Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Fernagut, Pierre Olivier ^a   Li, Qin ^b,c   Dovero, Sandra ^a   Chan, Piu ^d   Wu, Tao ^d   Ravenscroft, Paula ^b   Hill, Michael ^b   Chen, Zhenwen ^e   Bezard, Erwan ^a,c  

^a UMR 5287   (France)

^b Williams House   (United Kingdom)

^c INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; DOPAMINE TRANSPORTER; LEVODOPA; SODIUM CHLORIDE; ANTIPARKINSON AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; AUTORADIOGRAPHY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; LONG TERM CARE; MACACA; NONHUMAN; PARKINSON DISEASE; PROTEIN BINDING; PROTEIN EXPRESSION; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; CORPUS STRIATUM; MACACA MULATTA; METABOLISM; METHODOLOGY; PATHOLOGY;

ANIMALIA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; AUTORADIOGRAPHY; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; LEVODOPA; MACACA MULATTA; PARKINSON DISEASE, SECONDARY; PROTEIN BINDING; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 78649504565     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014053     Document Type: Article

References (56)

1. Marek K, Innis R, van Dyck C, Fussell B, Early M, et al. (2001) [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 57: 2089-2094.
2. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ (1998) Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 64: 314-319.
3. Nurmi E, Ruottinen HM, Kaasinen V, Bergman J, Haaparanta M, et al. (2000) Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT. Ann Neurol 47: 804-808.
4. Winogrodzka A, Bergmans P, Booij J, van Royen EA, Janssen AG, et al. (2001) [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease. J Neural Transm 108: 1011-1019.
5. Pirker W, Djamshidian S, Asenbaum S, Gerschlager W, Tribl G, et al. (2002) Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord 17: 45-53.
6. Morrish PK, Sawle GV, Brooks DJ (1996) An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 119(Pt 2): 585-591.
7. Parkinson (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287: 1653-1661.
8. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, et al. (2004) Levodopa and the progression of Parkinson's disease. N Engl J Med 351: 2498-2508.
9. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, et al. (2003) Slower progression of Parkinson's disease with ropinirole versus levodopa: The REALPET study. Ann Neurol 54: 93-101.
10. Ahlskog JE (2003) Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 60: 381-389.
11. Marek K, Jennings D, Seibyl J (2002) Do dopamine agonists or levodopa modify Parkinson's disease progression? Eur J Neurol 9(Suppl 3): 15-22.
12. Montgomery EB, Jr. (2003) Agonists versus levodopa in PD: the thrilla of whitha. Neurology 61: 1462; author reply 1462-1463.
13. Morrish PK (2003) Real-PET and CONSORT. Ann Neurol 54: 692; author reply 692-693.
14. Morrish PK (2003) REAL and CALM: what have we learned? Mov Disord 18: 839-840.
15. Bezard E, Ferry S, Mach U, Stark H, Leriche L, et al. (2003) Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 9: 762-767.
16. Ahmed MR, Berthet A, Bychkov E, Porras G, Li Q, et al. Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease. Sci Transl Med 2: 28ra28.
17. Bezard E, Gerlach I, Moratalla R, Gross CE, Jork R (2006) 5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease. Neurobiol Dis 23: 77-86.
18. Gold SJ, Hoang CV, Potts BW, Porras G, Pioli E, et al. (2007) RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease. J Neurosci 27: 14338-14348.
19. Bezard E, Imbert C, Deloire X, Bioulac B, Gross CE (1997) A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. Brain Res 766: 107-112.
20. Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, et al. (2001) Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinelesioned macaque model of Parkinson's disease. J Neurosci 21: 6853-6861.
21. Imbert C, Bezard E, Guitraud S, Boraud T, Gross CE (2000) Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey. J Neurosci Methods 96: 71-76.
22. Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD (1995) Chronic LDOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Mov Disord 10: 731-740.
23. Brotchie JM, Fox SH (1999) Quantitative assessment of dyskinesias in subhuman primates. Mov Disord 14(Suppl 1): 40-47.
24. Hill MP, Ravenscroft P, Bezard E, Crossman AR, Brotchie JM, et al. (2004) Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. J Pharmacol Exp Ther 310: 386-394.
25. Prunier C, Bezard E, Montharu J, Mantzarides M, Besnard JC, et al. (2003) Presymptomatic diagnosis of experimental Parkinsonism with 123I-PE2I SPECT. Neuroimage 19: 810-816.
26. Meissner W, Prunier C, Guilloteau D, Chalon S, Gross CE, et al. (2003) Timecourse of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease. Mol Neurobiol 28: 209-218.
27. Francois C, Yelnik J, Percheron G (1996) A stereotaxic atlas of the basal ganglia in macaques. Brain Res Bull 41: 151-158.
28. Miller RG (1981) Simultaneous statistical inference. New York: Springer.
29. Morrish PK (2003) How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease? Mov Disord 18(Suppl 7): S63-70.
30. Ravina B, Eidelberg D, Ahlskog JE, Albin RL, Brooks DJ, et al. (2005) The role of radiotracer imaging in Parkinson disease. Neurology 64: 208-215.
31. Zigmond MJ (1997) Do compensatory processes underlie the preclinical phase of neurodegenerative disease? Insights from an animal model of parkinsonism. Neurobiol Dis 4: 247-253.
32. Stanic D, Parish CL, Zhu WM, Krstew EV, Lawrence AJ, et al. (2003) Changes in function and ultrastructure of striatal dopaminergic terminals that regenerate following partial lesions of the SNpc. J Neurochem 86: 329-343.
33. Scheller D, Chan P, Li Q, Wu T, Zhang R, et al. (2007) Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease. Exp Neurol 203: 415-422.
34. Scherfler C, Donnemiller E, Schocke M, Dierkes K, Decristoforo C, et al. (2002) Evaluation of striatal dopamine transporter function in rats by in vivo beta-[123I]CIT pinhole SPECT. Neuroimage 17: 128-141.
35. Dresel SH, Kung MP, Plossl K, Meegalla SK, Kung HF (1998) Pharmacological effects of dopaminergic drugs on in vivo binding of [99mTc]TRODAT-1 to the central dopamine transporters in rats. Eur J Nucl Med 25: 31-39.
36. Innis RB, Marek KL, Sheff K, Zoghbi S, Castronuovo J, et al. (1999) Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT. Mov Disord 14: 436-442.
37. Schillaci O, Pierantozzi M, Filippi L, Manni C, Brusa L, et al. (2005) The effect of levodopa therapy on dopamine transporter SPECT imaging with(123)I-FPCIT in patients with Parkinson's disease. Eur J Nucl Med Mol Imaging 32: 1452-1456.
38. van de Giessen EM, de Win MM, Tanck MW, van den Brink W, Baas F, et al. (2009) Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3. J Nucl Med 50: 45-52.
39. van Dyck CH, Malison RT, Jacobsen LK, Seibyl JP, Staley JK, et al. (2005) Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med 46: 745-751.
40. Newberg A, Lerman C, Wintering N, Ploessl K, Mozley PD (2007) Dopamine transporter binding in smokers and nonsmokers. Clin Nucl Med 32: 452-455.
41. Chen PS, Yang YK, Yeh TL, Lee IH, Yao WJ, et al. (2008) Correlation between body mass index and striatal dopamine transporter availability in healthy volunteers-a SPECT study. Neuroimage 40: 275-279.
42. Weintraub D, Newberg AB, Cary MS, Siderowf AD, Moberg PJ, et al. (2005) Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. J Nucl Med 46: 227-232.
43. Parish CL, Stanic D, Drago J, Borrelli E, Finkelstein DI, et al. (2002) Effects of long-term treatment with dopamine receptor agonists and antagonists on terminal arbor size. Eur J Neurosci 16: 787-794.
44. Guigoni C, Dovero S, Aubert I, Li Q, Bioulac BH, et al. (2005) Levodopainduced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning. Eur J Neurosci 22: 283-287.
45. Winogrodzka A, Booij J, Wolters E (2005) Disease-related and drug-induced changes in dopamine transporter expression might undermine the reliability of imaging studies of disease progression in Parkinson's disease. Parkinsonism Relat Disord 11: 475-484.
46. Gnanalingham KK, Robertson RG (1994) The effects of chronic continuous versus intermittent levodopa treatments on striatal and extrastriatal D1 and D2 dopamine receptors and dopamine uptake sites in the 6-hydroxydopamine lesioned rat-an autoradiographic study. Brain Res 640: 185-194.
47. Ikawa K, Watanabe A, Kaneno S, Toru M (1993) Modulation of [3H]mazindol binding sites in rat striatum by dopaminergic agents. Eur J Pharmacol 250: 261-266.
48. Rioux L, Frohna PA, Joyce JN, Schneider JS (1997) The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys. Mov Disord 12: 148-158.
49. Gordon I, Weizman R, Rehavi M (1996) Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur J Pharmacol 298: 27-30.
50. Laruelle M, Baldwin RM, Malison RT, Zea-Ponce Y, Zoghbi SS, et al. (1993) SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 13: 295-309.
51. Moody CA, Granneman JG, Bannon MJ (1996) Dopamine transporter binding in rat striatum and nucleus accumbens is unaltered following chronic changes in dopamine levels. Neurosci Lett 217: 55-57.
52. Thibaut F, Bonnet JJ, Vaugeois JM, Costentin J (1996) Pharmacological modifications of dopamine transmission do not influence the striatal in vivo binding of [3H]mazindol or [3H]cocaine in mice. Neurosci Lett 205: 145-148.
53. Torres GE, Gainetdinov RR, Caron MG (2003) Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci 4: 13-25.
54. Emond P, Garreau L, Chalon S, Boazi M, Caillet M, et al. (1997) Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(49-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta-(39,49-disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter. J Med Chem 40: 1366-1372.
55. Hall H, Halldin C, Guilloteau D, Chalon S, Emond P, et al. (1999) Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [125I]PE2I. Neuroimage 9: 108-116.
56. Bove J, Prou D, Perier C, Przedborski S (2005) Toxin-induced models of Parkinson's disease. NeuroRx 2: 484-494.